CareDx

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CareDx reports solid Q4 earnings, eyes profitable growth in 2023

CareDx delivered strong financial results, focusing on profitable growth and strategic initiatives to drive revenue and market leadership.
While facing challenges such as fluctuating transplant volumes and market risks, the company is actively pursuing opportunities for expansion and innovation.
Overall, CareDx's performance, strengths, and proactive approach to challenges and opportunities position it for continued success and growth in the coming year.

CareDx reports Q1 2023 operational success amidst billing challenges

CareDx faced billing challenges impacting Medicare reimbursement but maintained strong operational performance and financial profile. The company is focused on mitigating financial impacts, managing cash flow, and pursuing growth opportunities through new modalities and publications.

CareDx reports Q2 revenue, faces Billing Article impact challenges

CareDx navigated challenges in Q2 2023 with a focus on financial strength, operational excellence, and strategic growth initiatives, despite a decline in Testing Services revenue.
The company's strong cash position, successful strategic executions, and pipeline catalysts position it well for future growth and expansion across Medicare and commercial plans.
While facing uncertainties and cost-saving initiatives, CareDx remains committed to achieving adjusted EBITDA positivity and overcoming challenges to drive long-term value for stakeholders.

CareDx reports solid Q3 earnings, eyes growth through expanded coverage

CareDx's Q3 2023 performance reflects revenue growth and improved EBITDA, driven by key business segments.
While facing challenges like CEO transition and payer coverage, the company is well-positioned for growth opportunities.
Strategic initiatives focusing on expanding coverage and driving testing volume growth indicate a positive outlook for CareDx.

CareDx surpasses revenue targets, eyes growth in transplant services

CareDx delivered strong financial performance in 2023, exceeding revenue guidance and focusing on strategic growth initiatives for 2024.
Despite facing challenges such as ongoing patent litigation and CEO search, the company is well-positioned to drive profitability and expand its offerings.
Opportunities for revenue growth exist in digital solutions, lab products, and transplant services, with potential catalysts for growth on the horizon.
CareDx's advocacy efforts and commercial expansions underscore its commitment to innovation and patient access in the transplant space.

CareDx reports robust Q1 earnings, raises guidance amidst market expansion

CareDx delivered strong financial results, showcasing growth across key business segments and improving EBITDA performance.
The company's focus on innovation, market expansion, and cost management positions it well for future growth and profitability.
With a solid cash position, positive clinical data, and expanded market coverage, CareDx is poised for continued success in the healthcare sector.

CareDx reports strong Q2 earnings, raises FY guidance confidently

CareDx delivered robust financial results in Q2 2024, driven by revenue growth, improved adjusted EBITDA, and successful validation studies for its diagnostic solutions.
The company's raised revenue guidance, expanding payer coverage, and planned Investor Day reflect a positive outlook and strategic focus on long-term growth.
While facing challenges in a competitive landscape, CareDx remains well-positioned to leverage opportunities in transplant diagnostics and healthcare innovation.
Investors can be optimistic about CareDx's performance, innovation pipeline, and strategic initiatives aimed at sustainable growth and market leadership.

CareDx reports robust Q3 earnings, targets $500M revenue by 2027

CareDx delivered strong financial performance in Q3 2024, driven by revenue growth, improved margins, and operational efficiencies.
The company's strategic initiatives to engage transplant centers and expand payer coverage have yielded positive results.
While facing challenges in operational execution and sustaining growth, CareDx remains optimistic about its future prospects and revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need

On National Donor Day, CareDx Applauds Patient Advocacy Efforts Aimed at Increasing Donations for the Thousands of Patients Waiting for a Transplant

CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure

CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education Program, to Host “Heart Health” Webinar for Transplant Patients

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the Raymond James 43rd Annual Institutional Investors Conference.

CareDx To Participate In Upcoming Conferences

ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients

Landmark ADMIRAL Study Publication with CareDx's AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance

The stock price of CareDx, Inc. (Nasdaq: CDNA) increased by 18.48% in the most recent trading session. This is why it happened.

CareDx Stock (CDNA): Why The Price Surged Today

ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant Recipients Navigating the COVID-19 Pandemic ALARM Study Publication Shows Use of AlloSure for Home-Based, Non-invasive Surveillance Monitoring Can Provide a Safer Option for Lung Transplant Recipients Navigating the COVID-19 Pandemic

NIH Study Shows Using CareDx's AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

Completing AlloMap Kidney CLIA Validation Represents the Next Step to Offering a More Comprehensive, Multimodality Assessment of Organ Transplant Health Completing AlloMap Kidney CLIA Validation Represents the Next Step to Offering a More Comprehensive, Multimodality Assessment of Organ Transplant Health

CareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch

CareDx will Directly Support Organ Transplant Patients with Specialty Prescription Services CareDx will Directly Support Organ Transplant Patients with Specialty Prescription Services

CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy

Although CareDx (CDNA) recently received inquiries from the DOJ and SEC, the longer-term investment case remains intact. CDNA has only begun to scratch the surface on its total market opportunity and the company is pursuing multiple growth strategies that should keep sales increasing at a high rate.

CareDx: Short-Term Headwinds Will Pass, Longer-Term High Growth Investment Case Remains

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In CareDx To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - January 4, 2022) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CareDx Inc. ("CareDx" or the "Company") (NASDAQ: CDNA).If you suffered losses exceeding $50,000 investing in CareDx stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CDNA.

CareDx Investor Notice

NEW YORK, Dec. 19, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) resulting from allegations that CareDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased CareDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages CareDx, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - CDNA

OAKLAND, Calif.--(BUSINESS WIRE)---- $CDNA #CDNA--Gibbs Law Group is investigating potential legal claims on behalf of CareDx investors.

Lost Money in CareDx, Inc.?

1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection 1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection

CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes

New York, New York--(Newsfile Corp. - December 8, 2021) - WHY:Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) resulting from allegations that CareDx may have issued materially misleading business information to the investing public.SO WHAT: If you purchased CareDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency...

CDNA Shareholder Alert: Rosen, Top Ranked Global Investor Counsel, Encourages CareDx, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - CDNA

NEW YORK, Dec. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of CareDx, Inc. (NASDAQ: CDNA) resulting from allegations that CareDx may have issued materially misleading business information to the investing public. SO WHAT: If you purchased CareDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages CareDx, Inc. Investors to Inquire About Securities Class Action Investigation - CDNA

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CareDx, Inc ("CareDx" or "the Company") (NASDAQ: CDNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CareDx released its Q3 2021 results on October 28, 2021. The Company...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CareDx, Inc and Encourages Investors with Losses to Contact the Firm

This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.

Bear Of The Day:CareDX

Inari Medical

Nevro

It doesn't take a lot to own a piece of these rapidly growing healthcare businesses.

3 Unstoppable Growth Stocks You Can Buy for Less Than $100 Right Now

San Francisco, California--(Newsfile Corp. - November 26, 2021) - Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now. Visit: http://www.hbsslaw.com/investor-fraud/CDNA Contact An Attorney Now: CDNA@hbsslaw.com 844-916-0895CareDx, Inc. (CDNA) Investigation: The investigation centers on the accuracy of CareDx's statements concerning its business practices, accounting, and public reporting, particularly pertaining to the company's kidney testing and phlebotomy services.On Oct. 28,

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- WeissLaw LLP, a national shareholders' rights law firm, is investigating possible false claims, accounting and reporting practices and breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and certain Company officers of CareDx, Inc. (NASDAQ: CDNA) ("CareDx" or the "Company"), which has led to investigations by the U.S. Department of Justice ("DOJ") and the Securities and Exchange Commission ("SEC") concerning "certain business practices related to [CareDx's] kidney testing and phlebotomy services." If you own CareDx shares and wish to discuss this investigation, or share information which you have, or if you have any questions concerning this notice or your rights or interests, visit our website at https://www.weisslaw.co/news-and-cases/cdna    Or please contact: Josh Rubin, Esq   stocks@weisslaw.co  (212) 682-3025.

SHAREHOLDER ALERT: WeissLaw LLP Investigates CareDx, Inc.

LOS ANGELES, Nov. 23, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CareDx, Inc ("CareDx" or "the Company") (NASDAQ: CDNA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CareDx, Inc and Encourages Investors with Losses to Contact the Firm

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) -- The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced its inclusion on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. This marks the third consecutive year that CareDx has been included on the Deloitte Technology Fast 500.

CareDx Named One of the Fastest-Growing Companies in North America on the Deloitte Technology Fast 500™ for the Third Consecutive Year

Los Angeles, California--(Newsfile Corp. - November 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CareDx, Inc ("CareDx" or "the Company") (NASDAQ: CDNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CareDx released its Q3 2021 results on October 28, 2021. The Company...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CareDx, Inc and Encourages Investors with Losses to Contact the Firm

San Francisco, California--(Newsfile Corp. - November 16, 2021) - Hagens Berman urges CareDx, Inc. (NASDAQ: CDNA) investors to with significant losses to submit your losses now.Visit: http://www.hbsslaw.com/investor-fraud/CDNA Contact An Attorney Now: CDNA@hbsslaw.com 844-916-0895CareDx, Inc. (CDNA) Investigation: The investigation centers on the accuracy of CareDx's statements concerning its business practices, accounting, and public reporting, particularly pertaining to the company's kidney testing and phlebotomy services.On Oct. 28,

CDNA INVESTIGATION: Hagens Berman Encourages CareDx (CDNA) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

Boston, Massachusetts--(Newsfile Corp. - November 16, 2021) - The Thornton Law Firm alerts investors that it is investigating CareDx, Inc. (NASDAQ: CDNA) for potential securities violations. Investors who currently own securities of CDNA may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/CareDx for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/CareDxOn October 28, 2021, after the market closed, CareDx, Inc. disclosed it is being investigated by...

News for CareDx Stock (CDNA)